Toll-like receptors: Role in inflammation and therapeutic potential

Authors

  • Emma Kay,

    1. Centre for Microvascular Research, William Harvey Research Institute, Barts and the London School of Medicine and Dentistry, Queen Mary University of London, London, UK
    Search for more papers by this author
  • Ramona S. Scotland,

    1. Centre for Microvascular Research, William Harvey Research Institute, Barts and the London School of Medicine and Dentistry, Queen Mary University of London, London, UK
    Search for more papers by this author
  • James R. Whiteford

    Corresponding author
    1. Centre for Microvascular Research, William Harvey Research Institute, Barts and the London School of Medicine and Dentistry, Queen Mary University of London, London, UK
    • Address for correspondence: James R. Whiteford, B.Sc., Ph.D., Centre for Microvascular Research, William Harvey Research Institute, Barts and the London School of Medicine and Dentistry, Queen Mary University of London, Charterhouse Square, London EC1M 6B, UK. Tel.: +44(0)20 7882 8241; Fax: 44 (0)20 7882 8257; E-mail: j.whiteford@qmul.ac.uk.

    Search for more papers by this author

Abstract

Inflammation is an essential process in response to injury and infection. However, under certain circumstances dis-regulation of this process can lead to pathologies such as rheumatoid arthritis, atherosclerosis, lupus, and is a contributory factor in the progression of many cancers. The Toll-like family of receptors (TLRs) has major roles in the initiation of the inflammatory response and as such has attracted much focus for their potential as therapeutic targets. Here we review the role of TLRs in the inflammatory response and associated disease and examine how this important family of molecules might be targeted for therapeutic benefit. © 2013 BioFactors, 40(3):284–294, 2014

Ancillary